Compare ESPR & GDOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESPR | GDOT |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 650.5M |
| IPO Year | 2013 | 2010 |
| Metric | ESPR | GDOT |
|---|---|---|
| Price | $2.64 | $11.10 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | $7.60 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 5.0M | 611.5K |
| Earning Date | 03-10-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | $403,135,000.00 | ★ $2,080,491,000.00 |
| Revenue This Year | $2.92 | $11.22 |
| Revenue Next Year | N/A | $5.55 |
| P/E Ratio | ★ N/A | $32.82 |
| Revenue Growth | ★ 21.31 | 20.69 |
| 52 Week Low | $0.73 | $6.59 |
| 52 Week High | $4.18 | $15.41 |
| Indicator | ESPR | GDOT |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 44.38 |
| Support Level | $2.37 | $10.23 |
| Resistance Level | $3.02 | $11.14 |
| Average True Range (ATR) | 0.18 | 0.31 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 54.44 | 59.79 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.